Idiopathic hypersomnia is characterized by excessive daytime sleepiness. It is often confused with narcolepsy. In addition to its psychiatric symptoms, it can overlap with narcolepsy and affect the ability to work and interact socially. Unfortunately, there is currently no FDA-approved treatment for idiopathic hypersomnia, which leaves many chronic insomnia sufferers unproductive.
Idiopathic hypersomnia is a rare neurological disorder that affects people’s ability to sleep. People with this disorder tend to experience excessive daytime sleepiness, which leads to difficulty waking up in the morning. In severe cases, the patient may also have difficulty waking up and may even take a nap during the day. Patients may also appear drunk or confused, or have difficulty concentrating during the day.
Global Idiopathic Hypersomnia Treatment Market is estimated at $242.4 million in 2021 and should present a CAGR of 8.7% over the forecast period (2022-2028).
Get Free Sample PDF Copy (Including Full Table of Contents, List of Tables and Figures, Chart) @
The increasing incidence of lifestyle-related illnesses such as anxiety, depression, etc. caused by changes in behavior, social activities, which affect the sleep cycle is the key factor responsible for the growth of the global idiopathic hypersomnia treatment market. These changes lead to anxiety, depression and other health problems, in which patients feel tired during the day and are more prone to hypersomnia. For example, according to the Anxiety and depression Association of America, anxiety disorders are the most common mental illness in the United States, affecting 40 million adults in the United States ages 18 and older, or 18.1% of the population each year.
Additionally, the increasing rate of hypersomnia diagnosis coupled with technological advancements for hypersomnia diagnosis are other major factors expected to fuel the growth of the global idiopathic hypersomnia treatment market. For example, the Multiple Sleep Latency Test (MSLT) is the standard tool used to diagnose narcolepsy and idiopathic hypersomnia, which is offered at AASM-accredited sleep centers in the United States.
The growing number of products in the pipeline for the treatment of idiopathic hypersomnia is also a major factor expected to drive the growth of the global idiopathic hypersomnia treatment market. For example, in January 2020, Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, initiated the Phase 1 study of a single dose intravenous infusion of TAK-925 in participants with idiopathic hypersomnia.
Since the outbreak of the COVID-19 virus in December 2019, the disease has spread to more than 100 countries around the world and the World Health Organization has declared it a public health emergency. According to the World Health Organization report, the outbreak of coronavirus disease (COVID-19) has resulted in more than 45 million people infected worldwide as of October 30, 2020. Due to the increasing prevalence of COVID- 19, major players operating in the Idiopathic Hypersomnia Treatment Market are focusing on the research and development of new products to support and combat the effect of COVID-19. The COVID-19 pandemic has impacted the global economy and, in turn, the Idiopathic Hypersomnia Treatment market. Quarantines, travel restrictions and social distancing measures are expected to lead to a sharp decline in business and consumer spending through the end of the third quarter of 2020
Global Idiopathic Hypersomnia Treatment Market – Splinting
Drug side effects such as aggressive behavior and addiction and lack of approved product are some of the key factors expected to limit the growth of the global idiopathic hypersomnia treatment market. Additionally, decreasing patient pool for clinical trials is also a major setback for the global idiopathic hypersomnia treatment market, which is expected to hamper the growth of the market.
Request a PDF brochure with the latest information @
Key players operating in the global idiopathic hypersomnia treatment market include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC and Merck & Co. Inc.
Reasons to Buy this Idiopathic Hypersomnia Treatment Market Report
◘ Save time conducting entry-level research by identifying the size, growth, and key players in the emerging Idiopathic Hypersomnia Treatment Market
◘ Use Five Forces Analysis to determine the competitive intensity and hence the attractiveness of the emerging Idiopathic Hypersomnia Treatment Market
◘ Key Company Profiles Reveal Details of Key Idiopathic Hypersomnia Treatment Market Players Emerging from Five Operations and Financial Performance
◘ Add weight to presentations and presentations by understanding the future growth prospects of the emerging Idiopathic Hypersomnia Treatment market with a five-year historical forecast
◘ Compares data from North America, South America, Asia-Pacific, Europe and Middle East Africa, plus individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, the growth rate of Idiopathic Hypersomnia Treatment market in 2028 is also explained. Additionally, type-wise and application-wise consumption tables and figures of Idiopathic Hypersomnia Treatment market are also provided.
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝟐𝟎𝟎𝟎 @ @
Chapter 1 Industry Overview
1.3 Scope of research
1.4 Market Analysis by Regions
1.5 Idiopathic Hypersomnia Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Impact on Idiopathic Hypersomnia Treatment Industry
Chapter 2 Global Idiopathic Hypersomnia Treatment Competition by Types, Applications, and Top Regions & Countries
2.1 Global Idiopathic Hypersomnia Treatment (Volume and Value) by Type
2.3 Global Idiopathic Hypersomnia Treatment (Volume and Value) by Regions
chapter 3 Generation market analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Idiopathic Hypersomnia Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Idiopathic Hypersomnia Treatment Market Analysis
Chapter 6 East Asia Idiopathic Hypersomnia Treatment Market Analysis
Chapter 7 Analysis of the Idiopathic Hypersomnia Treatment Market in Europe
Chapter 8 Analysis of the Idiopathic Hypersomnia Treatment Market in South Asia
Chapter 9 Analysis of the Idiopathic Hypersomnia Treatment Market in Southeast Asia
Chapter 10 Analysis of the Middle East Idiopathic Hypersomnia Treatment Market
Chapter 11 Africa Idiopathic Hypersomnia Treatment Market Analysis
Chapter 12 Analysis of the Idiopathic Hypersomnia Treatment Market in Oceania
Chapter 13 Analysis of the Idiopathic Hypersomnia Treatment Market in South America
Chapter 14 Company profiles and key figures in the field of idiopathic hypersomnia treatment
Chapter 15 Global Idiopathic Hypersomnia Treatment Market Forecast (2022-2028)
Chapter 16 conclusion
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.
Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702